QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:BGNE

BeiGene (BGNE) Stock Forecast, Price & News

$185.56
-4.82 (-2.53%)
(As of 09/26/2023 ET)
Compare
Today's Range
$185.31
▼
$190.05
50-Day Range
$185.56
▼
$225.13
52-Week Range
$124.46
▼
$280.62
Volume
132,639 shs
Average Volume
224,523 shs
Market Capitalization
$17.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$273.46
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

BeiGene MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
47.4% Upside
$273.46 Price Target
Short Interest
Healthy
1.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of BeiGene in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$730,020 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($12.86) to ($7.89) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

218th out of 964 stocks

Pharmaceutical Preparations Industry

84th out of 445 stocks

See Top Rated MarketRank™ Stocks Here

BGNE stock logo

About BeiGene (NASDAQ:BGNE) Stock

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BGNE Price History

BGNE Stock News Headlines

September 26, 2023 | americanbankingnews.com
BeiGene (NASDAQ:BGNE) Downgraded by StockNews.com to "Sell"
September 23, 2023 | americanbankingnews.com
Citigroup Increases BeiGene (NASDAQ:BGNE) Price Target to $290.00
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 23, 2023 | americanbankingnews.com
Equities Analysts Issue Forecasts for BeiGene, Ltd.'s FY2023 Earnings (NASDAQ:BGNE)
September 21, 2023 | markets.businessinsider.com
Citigroup Maintains Buy Rating for BeiGene: Here's What You Need To Know
September 21, 2023 | americanbankingnews.com
BeiGene (NASDAQ:BGNE) Given New $212.00 Price Target at Bank of America
September 21, 2023 | americanbankingnews.com
BeiGene (NASDAQ:BGNE) Shares Gap Down After Analyst Downgrade
September 19, 2023 | businesswire.com
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA ® (tislelizumab)
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 19, 2023 | businesswire.com
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA
September 19, 2023 | uk.finance.yahoo.com
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
September 19, 2023 | finanznachrichten.de
BeiGene, Ltd.: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA (tislelizumab)
September 19, 2023 | finance.yahoo.com
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
September 12, 2023 | benzinga.com
The Latest Analyst Ratings for BeiGene
September 1, 2023 | thestreet.com
Celgene Enters PD1 Market with BeiGene Deal
September 1, 2023 | businesswire.com
BeiGene to Present at the Morgan Stanley 21 st Annual Global Healthcare Conference
August 17, 2023 | investing.com
BeiGene fetches new 'buy' rating at Jefferies
August 17, 2023 | msn.com
Jefferies starts BeiGene at buy, cites deep pipeline, Novartis partnership
August 17, 2023 | cnbc.com
This biotech stock is a cancer-fighting 'powerhouse' with nearly 50% upside, says Jefferies
August 10, 2023 | benzinga.com
Sales Success Comes With Side Effects For Drug Maker BeiGene
August 3, 2023 | benzinga.com
SVP At This Health Care Company Sells $171K of Stock
August 3, 2023 | markets.businessinsider.com
Bernstein Keeps Their Hold Rating on BeiGene (BGNE)
August 2, 2023 | seekingalpha.com
BeiGene beats top and bottom line Q2 estimates
August 2, 2023 | finance.yahoo.com
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
July 21, 2023 | benzinga.com
Bragar Eagel & Squire, P.C. Is Investigating Viasat and BeiGene and Encourages Investors to Contact the Firm
July 21, 2023 | seekingalpha.com
BeiGene drug gets positive EMA panel opinion for esophageal cancer
July 21, 2023 | finance.yahoo.com
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Company Calendar

Last Earnings
8/02/2023
Today
9/26/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
CUSIP
N/A
CIK
1651308
Web
www.beigene.com
Phone
(345) 949-4123
Fax
N/A
Employees
9,200
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$273.46
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$196.00
Forecasted Upside/Downside
+45.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($16.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,003,810,000.00
Net Margins
-95.67%
Pretax Margin
-93.14%
Return on Equity
-40.78%
Return on Assets
-27.95%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
3.13
Quick Ratio
2.90

Sales & Book Value

Annual Sales
$1.42 billion
Price / Sales
12.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$42.17 per share
Price / Book
4.44

Miscellaneous

Outstanding Shares
96,850,000
Free Float
89,678,000
Market Cap
$18.15 billion
Optionable
Optionable
Beta
0.71

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. John V. OylerMr. John V. Oyler (Age 55)
    Co-Founder, Exec. Chairman & CEO
    Comp: $2.05M
  • Dr. Xiaobin Wu Ph.D. (Age 61)
    Pres & COO
    Comp: $1.69M
  • Dr. Xiaodong Wang Ph.D. (Age 60)
    Co- Chairman of Scientific Advisory Board & Non-Exec. Director Co-Founder
    Comp: $250k
  • Ms. Julia Wang (Age 51)
    CFO & Principal Accounting Officer
    Comp: $964.2k
  • Mr. Wang Lai (Age 46)
    Global Head of R&D
    Comp: $996.92k
  • Ms. Liza Heapes
    Head of Investor Relations
  • Mr. Chan Lee
    Gen. Counsel & Sr. VP
  • Dr. Yan Qi
    Sr. VP & Head of Public Affairs - Greater China
  • Mr. Jason W. Radford (Age 41)
    Sr. VP of Strategy & Corp. Devel.
  • Dr. Mark Lanasa
    Sr. VP & Chief Medical Officer for Solid Tumors

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BGNE Stock - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

What is BeiGene's stock price forecast for 2023?

12 Wall Street analysts have issued 1-year price targets for BeiGene's shares. Their BGNE share price forecasts range from $196.00 to $350.00. On average, they expect the company's share price to reach $273.46 in the next year. This suggests a possible upside of 45.9% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2023?

BeiGene's stock was trading at $219.94 at the beginning of 2023. Since then, BGNE shares have decreased by 14.8% and is now trading at $187.40.
View the best growth stocks for 2023 here.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our BGNE earnings forecast.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported ($3.64) EPS for the quarter, missing analysts' consensus estimates of ($3.47) by $0.17. The company had revenue of $595.30 million for the quarter, compared to analysts' expectations of $501.07 million. BeiGene had a negative net margin of 95.67% and a negative trailing twelve-month return on equity of 40.78%. The business's quarterly revenue was up 74.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($5.56) EPS.

What ETFs hold BeiGene's stock?

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR), VanEck Biotech ETF (BBH), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Products ETF (BBP), Global X Aging Population ETF (AGNG), iShares Biotechnology ETF (IBB), BlackRock Future Health ETF (BMED) and Invesco NASDAQ Next Gen 100 ETF (QQQJ).

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital International Investors (6.51%), Baillie Gifford & Co. (3.40%), Temasek Holdings Private Ltd (3.11%), Capital International Inc. CA (0.95%), BlackRock Inc. (0.90%) and Artal Group S.A. (0.43%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Bros Advisors Lp Baker, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $187.40.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $18.15 billion and generates $1.42 billion in revenue each year. The company earns $-2,003,810,000.00 in net income (profit) each year or ($16.66) on an earnings per share basis.

How many employees does BeiGene have?

The company employs 9,200 workers across the globe.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at (345) 949-4123 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -